Us Bancorp \De\ Kodiak Sciences Inc. Transaction History

Us Bancorp \De\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$6.52 - $8.05 $4,779 - $5,900	-733 Reduced 49.1%	760 $5,000
Q3 2022 Oct 27, 2022	BUY	$7.57 - $12.5 $8,962 - $14,800	1,184 Added 383.17%	1,493 $12,000
Q2 2022 Aug 01, 2022	SELL	$5.04 - $9.48 $4,329 - $8,143	-859 Reduced 73.54%	309 $2,000
Q1 2022 May 11, 2022	BUY	$7.09 - $89.45 $7,791 - $98,305	1,099 Added 1592.75%	1,168 $9,000
Q4 2021 Feb 11, 2022	SELL	$80.85 - $128.49 $35,493 - $56,407	-439 Reduced 86.42%	69 $6,000
Q3 2021 Nov 10, 2021	BUY	$81.97 - $106.94 $14,508 - $18,928	177 Added 53.47%	508 $49,000
Q2 2021 Aug 05, 2021	SELL	$77.2 - $126.54 $4,786 - $7,845	-62 Reduced 15.78%	331 $31,000
Q1 2021 Apr 28, 2021	BUY	$110.45 - $164.47 $36,117 - $53,781	327 Added 495.45%	393 $45,000
Q4 2020 Feb 04, 2021	BUY	$60.78 - $154.03 $4,011 - $10,165	66 New	66 $10,000
Q3 2020 Nov 10, 2020	SELL	$45.05 - $59.27 $855 - $1,126	-19 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$42.74 - $66.25 $812 - $1,258	19 New	19 $1,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $417M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.